Separate terms with OR to return results that match either term.
 
Clear All

621 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date (Descending) Status
J0642 Levoleucovorin Khapzory 0.5mg Ancillary Therapy Chemoprotective Antidote No 2018 Oct. 1, 2019 In Use
J0896 Luspatercept Reblozyl 0.25mg Ancillary Therapy Erythropoiesis-Stimulating Agent No 2019 July 1, 2020 In Use
J9177 Enfortumab vedotin-ejfv Padcev 0.25mg Immunotherapy Drug Antibody Conjugate Nectin-4 No 2019 July 1, 2020 In Use
J9198 Gemcitabine HCl Infugem 100mg Chemotherapy Antimetabolite Pyrimidine Analog No 2018 July 1, 2020 In Use
J9246 Melphalan Evomela 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2016 July 1, 2020 In Use
J9358 Fam-trastuzumab deruxtecan-nxki Enhertu 1mg Immunotherapy Drug Antibody Conjugate HER2, topoisomerase, tetrapeptide No 2019 July 1, 2020 In Use
Q5119 Rituximab-pvvr Ruxience 10mg Immunotherapy Monoclonal Antibody CD20 No 2019 July 1, 2020 In Use
Q5120 Pegfilgratim-bmez Ziextenzo 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2019 July 1, 2020 In Use
J9227 Isatuximab-irtc Sarclisa 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Oct. 1, 2020 In Use
J9304 Pemetrexed Pemfexy 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2020 Oct. 1, 2020 In Use
C9069 Belantamab mafodotin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Jan. 1, 2021 No Longer Used
J9144 Daratumumab, hyaluronidase-fihj Darzalex Faspro 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Jan. 1, 2021 In Use
J9223 Lurbinectedin Zepzelca 0.1mg Chemotherapy Alkylating Agent Adduct Forming Agent No 2020 Jan. 1, 2021 In Use
J9281 Mitomycin Pyelocalyceal Instillation Jelmyto 1mg Chemotherapy Antitumor Antibiotic Alkylating Agent/Mitomycin No 2020 Jan. 1, 2021 In Use
J9316 Pertuzumab, Trastuzumab, Hyaluronidase-zzxf Phesgo 10mg Immunotherapy Monoclonal Antibody HER2 No 2020 Jan. 1, 2021 In Use
J9317 Sacituzumab govitecan-hziy Trodelvy 2.5mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Jan. 1, 2021 In Use
Q5122 Pegfilgrastim-apgf Nyvepria 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2020 Jan. 1, 2021 In Use
J9037 Belantamab mafodontin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 April 1, 2021 In Use
J9349 Tafasitamab-cxix MONJUVI 2mg Immunotherapy Monoclonal Antibody CD19 No 2020 April 1, 2021 In Use
Q2053 Brexucabtagene autoleucel Tecartus 2000000 Immunotherapy CAR-T CD-19 No 2020 April 1, 2021 In Use
J9348 Naxitamab Danyelva 1mg Immunotherapy Monoclonal Antibody GD2 No 2020 July 23, 2021 In Use
J9353 Margetuximab-cmkb Margenza 5mg Immunotherapy Monoclonal Antibody HER2 No 2021 July 23, 2021 In Use
Q5123 Rituximab-arrx Riabni 10mg Immunotherapy Monoclonal Antibody CD20 No 2021 July 23, 2021 In Use
C9024 (Daunorubicin AND Cytarabine) Liposome Vyxeos 1mg/2.27mg Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog No 2017 In Use
NA Alpelisib Piqray 200mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use

Found 621 results in 3 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.